Jo Isurnol
`lecllnecstuJsrld
`secueps
`
`116I AUYONVf
`r ltsgl InN 99 Shrn'IoA
`
`'parJrluur
`u?t uorsn]u
`ar{l l€ql
`'ro^a
`IUJrlnaCeurJ
`
`Iural pi
`'slalqel se qens
`puB'spl
`uec urelsds
`.{pee1c sr 1r;r
`pue 'u8tsap'ur
`
`.{€ur
`
`puu a{olruJ
`luq? snlErl
`'sraddorpi
`p1no,r Suruear
`Uaqr[ U
`
`flTCIJAV lAgIAgA
`
`sllBs IBcl+nacBurrBqd
`
`PUa '* tr.flTH0rg 'C flT,tT '+* g0ugg 'IAtr NgHdtrJS
`' US0OH)INOIAI 'C CTVNO0
`
`-ocrsdqd'dceur.reqd lelaua8-s1ps leJr?naJEurr€qd O sesBJqd,{ay
`-rxo1 'serl.radord l€Jl?.nateurreqd
`'dlqrqele.ruorq 'serpado.rd lEJlrrraqc
`-ocrsdqd'dceurreqd lerauaS-lecrlnaceru.reqd'slleS Er mat.tar'd8o1or
`-rxo1'sarlradord lecrlnecerureqd'd1r1rqe1e,reotq'sarlrado.rd Pcluaqc
`'f,1qrqn1os'uorlnlossrp sallredord lecrruaqcocrsdq4 o rrrarla.r'd8o1or
`tr .&rarlal 'slles lecrlnoteurJeqd;o setlrado.rd olldaloue8ro pue 'f1qtqe1s
`-reqd pue uolleralle uorldrosqe'slreJJa uoll€lnur.ro;-dltltqelte.teotg
`-eur.reqd-,{SoloJlxo; E ,r\erlal'slles leJrlnac€rureqd 3o scIlaul{osutll
`.{el^ar'sJ.lBs IEcIlneJ
`
`S'LNSTNOC
`
`oql JO 'dlucrrrdura uasoqc ualJo arB slua8e Sunuro;-1pg
`,tq palealas sr ruJoJ parra;ard aq?'pazrsaqluds slps dueur
`:srwq leJrlcerd e uo dpreurrrd slslruaqc pctlnaceurreqd
`luacrad pue 'uor1ezr1p1s,frc 3o asea 'sleualeru rr\eJ Jo lsoe
`-dq id1r1qe1s opnlcur suol?€raplsuoc cISBq .raq16 'p1ad
`'8nrp rynq Sutlpsar aql Jo dlqrqe.trog pue 'dlrcrdocso.r8
`eq1 3u11e1pa.rd 3o deltt aIqBIIar ou sI aratll 'd1a1eun1.ro;un
`oq? Jo Jor^Br{eq aql uo sarcads lIBs rBIncI1.rBd e;o acuangut
`yo slps dueur .ral;e uala'aloruJaq?rnd'punoduroc
`lua.red
`luarcrlla ou 'paredard uaaq a,req lua8e JISBq arues aql
`l1es aq? Jo uollcalas alslIIIcBJ o? lslxa sanbruqcal Suruaa'rcs
`-nlos (crlaur4oceur.reqd paJISap aql llqqxa o1 ,t1a>1q lsour
`'sago.rd uol?BlnruroJ pue'd1qtq
`-ap uaaq'.ra.taltoq'a,rEq siapour 8ur>1ew-uotslcap aruos
`'aldurexa Jod 'ocueurro;rad 1ps lcrpard dlaq o1 padola.t
`lap,,'senbruqcal o^ ? paqlrcsap (1) outddy pue 3utp1p16
`pue .3'sISdIBue uralqord l€I?ualod,, pue ..sls^leua uoISIc
`-E^rrap alqu?ms lsour aq? Jo uol?3alas ar{l o? uroql paqdde
`aI{J 'lalqBl e se luaurdola^ap roJ pIcB cIuEEro uB Jo a^I?
`-rsselod aql pu€ pIJB aaq aql alaa\ poJoplsuoc saAIlBAIrap
`paseq aJB sanbruqcq qlog's?lus runlJlec pue'urntpos'utn
`asar$ Jo satlradord pcrSolorq pue'pcrs.(qd'lecnuaqc aql uo
`-ap JoJ enuo^B Sursrurord B JaJJO puB SaAI?BAIrap cgtcads
`'sruroJ 1ps purrldo 8utdo1a,r
`aq1 lnoq8no.rqi pas.radsrp dlaprm sr sll€s uo uotleurio;u1
`aql sossaJppe l{clq.t\ Jo qcnu 'arn1ura1r1 petlnacerureqd
`a^r?cB aql Jo as?alar ar{l Suolord ol uollBturoJ ?lES Jo asn
`Snrp alqe.rrsopun snoIJBA SuIlsuIurIIa dqaraql'luauoduroc
`^\al^ar
`?sEI aql Jo arnlBralq s^a^rns
`slI{J '(9-z) salFadord
`sarFadoJd aql uaa^qaq suoslJ€druoc Surzrseqdrua 'sread 96
`oslB papnlcul 'punoduoc oruEs ar{lJo surroJ lIBs ?uaraJJlp Jo
`asodJnd rno 'sruroJ l[ES lnJasn flet1ua1od;o UoISSnJSIp B sI
`lualaJJrp dueur aq1 Jo ^\aIAJaAo
`u8 ?uasald ol :ploJo^\l sI
`pue uasoqc aq uBJ salBplpu€J Snrp alau qclqd'uro4 slles
`
`| / ll6t ttonuop'I oN'99'IoA
`
`68Lgtz
`
`OI
`OI
`II
`II
`'I8I
`1I
`VT
`II
`9I
`9I
`9I
`9I
`9I
`
`" " s??rs ptas1 K.1nt1ua1o4
`''' "' salpnls ytnutatl'tu)ts,(t1,1
`" " elBU uorlnlossl(
`
`,{1lllqulS
`
`' Kltltqnymonoq
`"'i"
`' s?taJJg uollulnlurod
`: *#i{fh|ii:i;$'
`
`:: ::::: ::. :: :::: ::::: :"j11i*i{:l'iffi:il3
`::::::::::
`:
`:
`
`lcaJJg PcrSoloceurreq6
`" "'
`'" " srsllurg
`. . . . . . . . . . . : . . . . . . . . . . . . . . . . . . .:y?!;::??::":?JJ;;iiJ#
`' ' uoJ llES Jo '{lIrIxoJ
`urro.d ?TBS lo dltctxo;
`"' suolsnpu1c
`sDuala|aA
`""
`-rBqJ crruouoca puE'pcrs.{qd'prr8olotq'pcturaqc eq;
`'pue palepdluBru aq uec slua8e IBuIcIpau Jo sJIlsIralJB
`'urroJ ?lBS B ol uolsJa,ruoc dq pezturtldo ua1;o 'acuaq
`dral e aq uBJ 'ralanoq '11es aler.rdoJdde aql Sursooq3
`o1 saq.rado.rd anbrun slredurr 1IBS t{cea acuts '>1se1 lFllJJlp
`'punoduroc luared aql
`
`'i""'
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 1
`
`

`
`Table I-FDA-Approved Commercially Marketed Salts
`
`Anion
`
`Acetate
`Benzenesulfonate
`Benzoate
`Bicarbonate
`Bitartrate
`Bromide
`Calcium edetate
`Camsylateb
`Carbonate
`Chloride
`Citrate
`Dihydrochloride
`Edetate
`Edisvlate'
`Estoiated
`Esylate''
`Fumarate
`Gluceptate/
`Gluconate
`Glutamate
`Glycollylarsanilates
`Hexvlresorcinate
`Hydrabamineh
`Hydrobromide
`Hydrochloride
`Hydroxynaphthoate
`
`Cation
`
`Percento
`
`"Anion
`
`Percento
`
`7.26
`0.25
`0.51
`0.13
`0.63
`4.68
`o.25
`0.25
`0.38
`4.t7
`3.03
`0.51
`0.25
`0.38
`0.13
`0.13
`0.25
`0.18
`0.51
`0.25
`0.13
`0.13
`0.25
`1.90
`42.98
`0.25
`
`Iodide
`ISethionatet
`Lactate
`Lactobionate
`MaIate
`Maleate
`Mandelate
`Mesylate
`Methylbromide
`Methylnitrate
`Methylsulfate
`Mucate
`Napsylate
`Nitrate
`Pamoate (Embonate)
`Pantothenate
`Phosphate/diphosphate
`Polygalacturonate
`Salicylate
`Stearate
`Subacetate
`Succinate
`Sulfate
`Tannate
`Tartrate
`Teoclatej
`Triethiodide
`
`2.O2
`0.88
`0.76
`0.13
`0.13
`3.03
`0.38
`2.02
`0.76
`0.38
`0.88
`0.13
`0.25
`0.64
`1.01
`0.25
`3.16
`0.13
`0.88
`0.25
`0.38
`0.38
`7.46
`0.88
`3.54
`0.13
`0.13
`
`Percenta
`
`Cation
`
`Percento
`
`Metallic:
`Organic:
`Aluminum
`BenzathineA
`0.66
`0.66
`Calcium
`10.49
`Chloroprocaine
`0.33
`Lithium
`0.33
`Choline
`1..64
`Diethanolamine
`Magnesium
`1.31
`0.98
`Ethvlenediamine
`Potassium
`10.82
`0.66
`Sodium
`Mejluminel
`6t.97
`2.29
`Zinc
`2.95
`Procaine
`0.66
`n Percent is based on total number ofanionic or cationic salts in use through 19?4. 6 Camphorsulfonate. " 1,2-Ethanedisulfonate. d Lauryl sulfate
`t 2-Hydroxyethanesulfonate.
`,' Ethanesulfonate. / Glucohepronuls. sp-Glycollamidophenylarsonate. h N,N'-Di(dehydroabietyl)ethylenediamine.
`r 8-Chlorotheophyllinate. t ,rtr,N'-Dibenzylethylenediamine. I N-Methylglucamine.
`
`to assemble data that will provide, for the student and
`practitioner alike, a rational basis for selecting a suitable
`salt form.
`
`POTENTIALLY USEFUL SALTS
`Salt formation is an acid-base reaction involving either
`a proton-transfer or neutralization reaction and is there-
`fore controlled by factors influencing such reactions.
`Theoretically, every compound that exhibits acid or base
`characteristics can participate in salt formation. Particu-
`larly important is the relative strength of the acid or
`base-the acidity and basicity constants of the chemical
`species involved. These factors determine whether or not
`formation occurs and are a measure of the stability of the
`resulting salt.
`The number of salt forms available to a chemist is large;
`surveys of patent literature show numerous new salts being
`synthesized annually. Various salts of the same compound
`often behave quite differently because of the physical,
`chemical, and thermodynamic properties they impart to
`the parent compound. For example, a salt's hydrophobicity
`and high crystal lattice energy can affect dissolution rate
`and, hence, bioavailability. Ideally, it would be desirable
`if one could predict how a pharmaceutical agent's prop-
`erties would be affected by salt formation.
`Tables I and II list all salts that were commercially
`marketed through 1974. The list was compiled from all
`agents listed in "Martindale The Extra Pharmacopoeia,"
`
`2 I Journal of Pharmoceutical Sciences
`
`26th ed. (7). Table I categorizes all salt forms approved by
`the Food and Drug Administration (FDA), while Table II
`lists those not approved by the FDA but in use in other
`countries. (Only salts of organic compounds are considered
`because most drugs are organic substances.) The relative
`fre.quency with which each salt type has been used is cal-
`culated as a percentage, based on the total number of an-
`ionic or cationic salts in use through 1974. Because of
`simple availability and physiological reasons, the mono-
`protic hydrochlorides have been by far the most frequent
`choice of the available anionic salt-forming radicals, out-
`numbering the sulfates nearly six to one. For similar rea-
`sons, sodium has been the most predominant cation.
`Knowledge that one salt form imparts greater water
`solubility, is less toxic, or slows dissolution rate would
`greatly benefit chemists and formulators. In some cases,
`such generalizations can be made. Miller and Heller (8)
`discussed some properties associated with specific classes
`of salt forms. They stated that, in general, salt combina-
`tions with monocarboxylic acids are insoluble in water and
`lend themselves to repository preparations, while those of
`dicarboxylic acids confer water solubility if one carboxylic
`group is left free. Pamoic acid, an aromatic dicarboxylic
`acid, is an exception since it is used as a means of obtaining
`prolonged action by forming slightly soluble salts with
`certain basic drugs. Saias ef ol. (9) reviewed the use of this
`salt form in preparing sustained-release preparations.
`More recently, latentiation of dihydrostreptomycin (10)
`
`Table II-
`Salts
`
`Adipate
`Alginate
`Aminosalicl
`Anhydrome
`Arecoline
`Aspartate
`Bisulfate
`Butylbromir
`Camphoratr
`Digluconate
`Dihydrobror
`Disuccinate
`Glvcerophos
`Hemisulfate
`Hydrofluori
`Hydroiodidr
`Methyieneb
`Napadisylat
`Oxalate
`Pectinate
`Persulfate
`Phenyiethyl
`Picrate
`Propionate
`Thiocyanate
`Tosylate
`Undecanoat
`
`Cation
`
`Organic:
`Benetharn
`Clemizole
`Diethylan
`Piperazinr
`Trometha
`Metallic:
`Barium
`Bismuth
`
`" Percent
`through 1974
`a 1-p-Chlorc
`droxymethyl
`
`using pam
`action prel
`are disperl
`Alginic
`pharmacer
`and showr
`tions. A st
`that of pil
`dried to a r
`preparatic
`While liqu
`ride salts I
`that solid 1
`more effec
`nificantly
`Solid dose
`because it
`which hok
`commonly
`immediatr
`M6lek e
`action thrr
`tribution c
`by merely
`molecules
`l5rmphatic
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 2
`
`

`
`Table l-tr'DA-Approved Commercially Marketed Salts
`Percento
`
`Anion
`
`Percent"
`
`Table II-l
`Salts
`
`Acetate
`Benzenesulfonate
`Benzoate
`Bicarbonate
`Bitartrate
`Bromide
`Calcium edetate
`Camsylateb
`Carbonate
`Chloride
`Citrate
`Dihvdrochloride
`Edetate
`Edisvlate'
`Estoiated
`Esylate"
`Fumarate
`Gluceptate/
`Gluconate
`Glutamate
`Glycollylarsanilater
`Hexvlresorcinate
`Hydrabamineh
`Hydrobromide
`Hydrochloride
`Hydroxynaphthoate
`
`Cation
`
`1.26
`0.25
`0.51
`0.13
`0.63
`4.68
`0.25
`0.25
`0.38
`4.77
`3.03
`0.51
`0.25
`0.38
`0.13
`0.13
`0.25
`0.18
`0.51
`0.25
`0.13
`0.13
`0.25
`1.90
`42.98
`0.25
`
`,Anion
`
`Iodide
`Isethionatet
`Lactate
`Lactobionate
`Malate
`Maleate
`Mandelate
`Mesvlate
`Metirylbromide
`Methylnitrate
`Methylsulfate
`Mucate
`Napsylate
`Nitrate
`Pamoate (Embonate)
`Pantothenate
`Phosphate/diphosphate
`Polygalacturonate
`Salicylate
`Stearate
`Subacetate
`Succinate
`Sulfate
`Tannate
`Tartrate
`Teoclatej
`Triethiodide
`
`2.02
`0.88
`0.76
`0.13
`0.13
`3.03
`0.38
`2.02
`0.76
`0.38
`0.88
`0.13
`0.25
`0.64
`1.01
`0.25
`3.16
`0.13
`0.88
`0.25
`0.38
`0.38
`7.46
`0.88
`3.54
`0.13
`0.13
`
`Adipate
`Alginate
`Aminosalicyle
`Anhydrometl
`Arecoline
`Aspartate
`Bisulfate
`Butylbromidt
`Camphorate
`Digluconate
`Dihydrobrom
`Disuccinate
`Glycerophosp
`Hemisulfate
`Hydrofluorid
`Hydroiodide
`Methylenebis
`Napadisylate
`Oxalate
`Pectinate
`Persulfate
`Phenylethylb
`Picrate
`Propionate
`Thiocyanate
`Tosylate
`Undecanoate
`
`Cation
`
`Organic:
`Benethami
`Clemizoled
`Diethylami
`Piperazine
`Tromethar
`Metallic:
`Barium
`Bismuth
`
`" Percent ii
`through 1974.
`d 1-p-Chloroi
`droxymethyll
`
`using pam(
`action pret
`are dispers
`Alginic z
`pharmaceu
`and shown
`tions. A str
`that of pik
`dried to a s
`preparatio
`While liqu
`ride salts 1
`that solid 1
`more effec
`nificantly
`Solid dose
`because it
`which holc
`commonly
`immediate
`M6lek e
`action thrr
`tribution c
`by merely
`molecules
`lymphatic
`
`Percent"
`
`Cation
`
`Percent"
`
`Metallic:
`Organic:
`0.66
`Aluminum
`0.66
`Benzathineh
`10.49
`Calcium
`0.33
`Chkrroprocaine
`1.64
`Lithium
`0.33
`Choline
`1.31
`Magnesium
`0.98
`Diethanolamine
`10.82
`Potassium
`0.66
`Ethvlenediamine
`61.97
`Sodium
`2.29
`Megluminel
`2.95
`Zinc
`0.66
`Procaine
`n percent is based on total number ofanionic or cationic salts in use through_1974. bCamphorsulfonate. " 1,2-Ethanedisulfo-nate. d.Lauryl.sulfate.
`";;-dt;"li;ia"pt'""r,t'.""rte. I' AiN' Di(dehydroabietyl)ethylenediamine.
`t 2-Hydroxvethanesulfonate.
`. ntiri"".rirJ""t"-] di;;;1;;;;;;;
`I N-Methylglucamine.
`, g-chlorotheophyltinal,e. h N,N'-Dibenzylethylenediamine.
`
`to assemble data that will provide, for the student and
`practitioner alike, a rational basis for selecting a suitable
`salt form.
`
`POTENTIALLY USEFUL SALTS
`Salt formation is an acid-base reaction involving either
`a proton-transfer or neutralization reaction and is there-
`fore controlled by factors influencing such reactions.
`Theoretically, every compound that exhibits acid or base
`characteristics can participate in salt formation. Particu-
`larly important is the relative strength of the acid or
`base-the acidity and basicity constants of the chemical
`species involved. These factors determine whether or not
`formation occurs and are a measure of the stability of the
`resulting salt.
`The number of salt forms available to a chemist is large;
`surveys of patent literature show numerous new salts being
`synthesized annually. Various salts of the szrme compound
`often behave quite differently because of the physical,
`chemical, and thermodynamic properties they impart to
`the parent compound. For example, a salt's hydrophobicity
`and high crystal lattice energy can affect dissolution rate
`and, hence, bioavailability. Ideally, it would be desirable
`if one could predict how a pharmaceutical agent's prop-
`erties would be affected by salt formation.
`Tables I and II list all salts that were commercially
`marketed through 1974. The list was compiled from all
`agents listed in "Martindale The Extra Pharmacopoeia,"
`
`2 / Journal of Pharrnaceuticol Sciences
`
`26th ed. (7). Table I categorizes all salt forms approved by
`the Food and Drug Administration (FDA), while Table II
`lists those not approved by the FDA but in use in other
`countries. (Only salts of organic compounds are considered
`because most drugs are organic substances.) The relative
`flequency with which each salt type has been used is cal-
`culated as a percentage, based on the total number of an-
`ionic or cationic salts in use through 1974. Because of
`simple availability and physiological reasons, the mono-
`protic hydrochlorides have been by far the most frequent
`choice of the available anionic salt-forming radicals, out-
`numbering the sulfates nearly six to one. For similar rea-
`sons, sodium has been the most predominant cation.
`Knowledge that one salt form imparts greater water
`solubility, is less toxic, or slows dissolution rate would
`greatly benefit chemists and formulators. In some cases,
`such generalizations can be made. Miller and Heller (8)
`discussed some properties associated with specific classes
`of salt forms. They stated that, in general' salt combina-
`tions with monocarboxylic acids are insoluble in water and
`lend themselves to repository preparations, while those of
`dicarboxylic acids confer water solubility if one carboxylic
`group is left free. Pamoic acid, an aromatic dicarboxylic
`acid, is an exception since it is used as a means of obtaining
`prolonged action by forming slightly soluble salts with
`certain basic drugs. Saias et ol. (9) reviewed the use of this
`salt form in preparing sustained-release preparations.
`More recently, Iatentiation of dihydrostreptomycin (10)
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 3
`
`

`
`DIUAJJod
`
`poterlretr tr l(lelcreururo3 pero.rcldy-Vqg-uoN-Il olq"I
`stlss
`
`7,0'z
`880
`9r'0
`8r'0
`8r'0
`808
`880
`z0'7,
`9/'0
`88'0
`880
`8r'0
`gz'0
`19'0
`IO'I
`97,'0
`9r'8
`8I'0
`88'0
`9Z'0
`880
`88'0
`9r'L
`880
`t98
`8r'0
`8I'0
`
`olUA3JOd
`
`990
`67'0i
`19 I
`I8'I
`z8 0r
`t6'r9
`967,
`
`'a1e.;ps 1drne1
`'alBuoJInsauPq
`
`dq pa.torddu
`II alqBJ alrq
`raqlo w asn
`peJaprsuoc a,
`aArlBIor or{f
`-IBc sr pasn I
`-uB Jo roqwr
`Jo asnEcag'
`-ouou aql 's
`luanbaq 1so
`-1no'slucrpu
`-€aJ JBIrrUrS,
`'uorlBJ I
`Ja?B1r{ JalBaJ
`pFo^{ alBr r
`'sas?c atuos r
`(g) ra11eg pr
`sassBlc JrJrcs
`-BurqruoJ 1l€
`puB ralBll\ ur
`Jo asoql aIIt{1
`crldxoqrec ar
`aqdxoqrecrp
`8ururc1qo;o r
`qll^\ sllBs al
`srql lo Osn arl
`'suorlerudarr
`(91) urcdurol
`
`uoruY
`
`aludrpy
`a1eut31Y
`aleldctlesoututY
`a1e.r1rcauai.(qlaurorpdquy
`auIToceIY
`alelredsY
`eJalTnsrS
`aPtutolqldlng
`aleroqduu3
`aleuotnlSl0
`apturorqorplqlq
`alsultcnsl(
`al€qdsoqdoratdlN
`al€JInsIrxaH
`apuonUorp,{H
`aPtPoto.tPlg
`1 a1u1.{.I1es.;srqaua[{q}atr tr
`n aleldstpedeS
`a1€lex0
`al€ullrad
`alElTnsrad
`alernlrqreqldqlalduaq4
`alBJJrd
`aluuotdor4
`a1eue.{cotq;
`a1e1.{so;
`aleouuc0pull
`
`uoIlBc
`
`o?uacJod
`
`gr'0
`8r'0
`9Z'0
`8r'0
`8r'0
`9Z'0
`9Z'0
`8r'0
`8r'0
`8r'0
`8T'0
`8I'0
`88'0
`8I'0
`8I'0
`9Z'0
`8I'0
`€r'0
`9A'0
`8r'0
`8T'0
`8r'0
`8I'0
`8r'0
`8r'0
`8I'0
`8I'0
`
`D?uacJod
`
`:Jru?5J0
`.aurIueqlauag
`palozrIualS
`aururel.{q1erq
`aurzeradr6
`,aururBqJaluorJ
`:OIIIBletr{
`runrJB[l
`qlnruslg
`truolJEc pu€ cIuoIuB Jo Jaqunu ]€lo? uo pesEq sI luaJJod D
`asn ur s?.I€s
`'auiurelfqleueqdl.{zuag-p .'aleuoJlnsrpauapqlqde5l-g'1 e'tl6I q8nor{l
`-^q)srrJ,'aroz'prulzuaql.{q1aru1d-,1-",p;il:.11"-?il;H."{n:ffi51,iT:
`
`88'0
`88'0
`88'0
`86'0
`88'0
`
`e8'0
`86'0
`
`1
`
`-padelap B Jo uolleruroJ aq? ul pallnsar plce crourud Sursn
`qIBs aleorued Sutsn salpn?s snorarunN 'uotle.redard uotlcu
`'(gI-iI) arn?uralrl aql ?noq8no.rql pas;adstp ere
`3ur1cu-3uo1 e.redard ol pasn uaaq s€q osp pIcB ctutFly
`(91 ) peredard sem aleu#p urcduolda4s'spcllnaceurreqd
`-e.rederd as"elar-peurBlsns ur a^lltaJJa aq ol u^loqs puE
`sr 1ps aleur8p 8ut1ce-8uol E Jo aldruexa 3ut1tr1s V 'su0l1
`rolBrt\ allrals ut pasradsrp uaqM 'eu'rd.recoltd 1o ]e{1
`pu€
`aql ur InJesn punoJ s€^\ punoduoc sq1 '193_plos B o? palrp
`j9 suiroy a8esop cturpqlqdo 8ur1ce-3uo_1 go uorlereda.rd
`-olqcorpdq pue a1eur31e aql Jo suoll€redard ptnbq a1tq16
`paaoqs salpnls 'd1t.tl1ce JIloIu rBlIluISr ssassod slps apIJ
`ezrs pdnd palclJlsuoc sa>1eg a1eur31e aurd.recoltd pqos leql
`-8rs stsorur;o uollernp aql pas€arcut pue dla,rtlaaJJa arolu
`'suorlereda.rd plnbq aql qllrla pareduroc uaq,u d11uecg1u
`'alqegenu .{1uuo;tun aloru aq deur aurdrecoltd esop ptlog
`xrr?Eur 1aB aql q8norrll .{1lro1s arour sosnJJlp }l asn€caq
`aql Jo sdorp '1ser1uoa uI 'aAJosaJ ut Snrp aql sploq qclq^\
`asop aql asBaIaJ turo; a8esop uollnlos padoldura.{luoruuror
`'pmg 1e^Ilcunluoc aql o1 ,t1e1etp0urut
`Sur8uolo.rd;o derrr anbrun B pasllap (gf) 'to ?a {algl tr
`l.ip .qt l€ql pa^\ot{s daql luolleuuoJ ll€s q8nolq1 uot}cu
`porall€ dlparyeur aq plnor scllolql?ue IBraAas Jo uollnqlr?
`-olceu acws 'slles relncaloruorceur Surredo;d dlaraur dq
`aql roJ dlrur;;e uB o^Bq salctlred leplolloc pue solncalou
`pue'urc,{tuotl'utcdutoau'utcduroldarls'uralsds ctleqdu'ri1
`
`'
`
`lqSraru relncalotu qFFI q?yrl paulqruoc ara,tr uraf.rq1o1de.r1s
`-soqd ro JIuoJIns'sprce crldrcedlod se qcns spunoduroc
`;saarle,rtrap cruo.rndlod pue'sapr.reqccesdlod paluldroqd
`pacnpo.rd spunodruoc asaql Jo uoll€rlsplurpe
`l€ra?ual€d
`ailqrrr 'sporrad 3uo1 JoJ crlolqlluB eql Jo sla^al poolq /t\ol
`uraduolda.rls 'uostleduloc uI) 'q8tq a.ren qa.lal qdulrtl
`srql ('s1ara1 qdurdl a\ol lnq sla^al poolq q8tq ane8 alBJIns
`o1 urodruoldarls eql pasn?J uollnqlJlslp uI uol?Broll€
`crleqdurdl acurs 'r{poq aq1 q8no.rql a8essed s1r 8uo1o.td
`'no1s altnb sI uoI?BIncJIJ
`ol punoJ uaaq s€q urJoJ 1l3s B Jo acloqc alerrdoldde aq;,
`punoduroc due 1eq1 pazII€uoIlEJ aq u€c 11 'd1tctxo1 aJnpaJ
`{urrp pu€ pooJ Jo ursqoqBlau l€rurou aql q}p\ pal€Icoss€
`Eursooqc 3o qceordde aqJ 'clxoluou dletluassa aq lsnru
`pazrloqulau Jo palarcxa .{lpear ere leql slBcIpBJ crueS.ro
`^\au
`lcolas 01 t{clqa uroq secuulsqns Jo ss€lJ
`e dn pauado
`aseq 8uor1s ar{l Jo sIIBS uIBlJac 'aldruexa Jod 'ruJoJ llES s
`Jraql u€q}
`tIXo? ssel dlqe.reprsuoc aq o1 ualo.td aA€q auqoqJ
`.;o sarlrado.rd pue uorle.redard aq;, 'punoduroc luared
`oJa^\ salrleAr.rap aurlldqdoaql yo salras € Jo slles auqoqc
`aleuqldqdoaql auloqc ?pql u^\or{s sB^\ 1I ptre'(61) pagodar
`raqlo slr .ro aullldqdoaql ueq? OsoT ra?Bar8 e passessod
`ssal aq plno^\ lue8e syql lBrI? palelnlsod se.u ?I '(02) s?IB!
`slr,, asneJaq 'auq1fqdourruB uer{l lcerl IC oql ol 8ul?€?lrrl
`-uou .{1a1a1duoc lsorulB ue st 'aurloqc 'luanlllsuoc cIS€q
`crSolorsdqd aql q acuelJodurl 1enlce Jo ocuelsqns clxol
`auqoqc Jo uollEr€dald aql 01 pel asuopl^a stq1, ,,'durouoca
`sacueqrnlsrp IC aql ecnpar o1 1dura11e ue se (16) aleldcqes
`sarpnls F?ruITC'uoll€J?slultupe aleldcqes r{1l.^a palelcossB
`aouaprJul Ja,t\ol B pallcqa aleldctps aulloqc 1€ql poleJlpul
`Jo se^a pu€
`'sasop .raq8tq uI paleralol se^l 'ssorlslp IC Jo
`prce cq,{cqesldlace S3,&\ uBql luarled aql o? ?IJauaq raleerS
`'(ut.rtdse)
`sE pasn uaaq OAEI{ osl" suIluB}IA plc€ puB splcB oulluY
`-pBoc lBr{1 acuapr^a aql uo pasBg 's1ua8e Suturro;-1ps
`-lqllue aprsocdlSoulru€ qll^\ splce oultu€ Jo uoll€rlslultu
`Jo sIIBS plc€ oultue Jo salJas e 'd1tcrxo1 rlaql pacnpoJ scllo
`auo lnq il€ uI '(ZZ) pareda.rd s€^\ ulc^uroldarlsorpdqtp
`ar{l uBI{l Jo/r\ol oJa,!\ S?IBS asaql Jo saI}DIxo? alnce aq1 'asec
`aqJ, 'a?BJIns aql Jo dlrctxol
`ol€uoqlo?uBd pue al€qrocs€
`aql uet{l clxol ssal aq ol u.4aoqs pu€ pazlsaqluds a.ram osle
`"1nqro".n
`"tTrT#
`lsaq;rq ar{lp'r{
`eq1'paredard slps aq?Jo
`
`slps Suturroy JoJ pasn dluouuroc lsoul sulru€l$ ar{J
`cruaqlolued pu€ clqJocse are d1rctxo1. pacnpar Sutltqtqxa
`cruaq?oluBd asn 01 lsrrJ aql a;am (96) '?o ?a rallay 'splce
`sacduroldarls crsBq aql ,,3u1.{Jlxo?4p,, Jo suEaur B sE pIcB
`-uaqlolued aql Jo uollEr?slullup€
`leraluarBd'scllolqlluB
`-8rs e peq urc.{uroldarlso.rpdqrp pue urcdurolda.rls Jo sal€
`slec ur dlrcrxolo.rneu alnc€ Jo acuaplcul pacnpor dlluect;1u
`$Z-nZ) sarpnls luanbasqng 'so?eJlns aq? qlp\ par€druoc
`sB
`selBuer{lolrrEd aq1 1eq1 pa/roqs pue Surpury sF{l pa?roddns
`aleqrocsB aqJ/ 'CIxo? ssal aJE oslB utcdurot.l pue urcduroau 5o
`pcrSoloceur.reqd s1r pue pazlsaqlu^{s se.u utc.{uropuealo ;o
`-calur relncsnurerlul uodn '(66) pelrodar ara,l. satl.radord
`-soqd eql uBql uollBllJrl ssol paanpo.td 1t 's1er uI uoll
`'a1eqd
`JO a?{oqBlaur snoncouul uB (pIcB clozuaqopruelacy-d
`pasn uaaq suq (aulJn pue poolq I€rurou ut luasa.rd pIcB cIToJ
`qllnd s?lBs alq€ls sp1ar.{ 1r '.re1nct1red uI 's?lBS SutrBda.rd ut
`s?cnpoJd cldocsoJ8^q uJoJ ol pual aslAraq?o }€ql saulurB
`'(0g) sluauoduroc prcD leuolluoluoc qll^
`llES E Surururalap dq uasoqc sI ruroJ ll€s aql ua?Jo
`
`t / lL6I KtnnuoT'L oN'99 toA
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 4
`
`

`
`component that will pharmacologically antagonize an
`unfavorable property or properties exhibited by the basic
`agent. Salts of N-cyclohexylsulfamic acid are an example
`of the practical application of this approach. N-Cyclo-
`hexylsulfamic acid salts, better known as cyclamates, have
`a characteristic sweet, pleasing taste. Although presently
`under investigation by the FDA for potentially carcino-
`genic properties, salts incorporating this compoqnd can
`render unpleasant or bitter-tasting drugs acceptabie. For
`example, the cyclamates of dextromethorphan and
`chlorpheniramine exhibit greatly improved bitterness
`thresholds compared to commonly occurring salts (81.).
`Furthermore, their stability in aqueous solution was de-
`scribed as good when maintained at a pH not greater than
`4.
`
`N-Cyclohexylsulfamic acid salts of thiamine hydro-
`chloride and lincomycin also have been synthesized. Thi-
`amine N-cyclohexylsulfamate hydrochloride was reported
`to have a more pleasant taste than other thiamine salts
`while having an equal or greater stability (32). Lincomycin
`cyclamate, shown to possess an enhanced thermal stability
`over its hydrochloride, was prepared (33) to test the hy-
`pothesis that reduced lincomycin absorption in the pres-
`ence of small quantities of cyclamates was due to a simple
`metathetic reaction. However, this assumption was found
`not to be true. An extensive study of the preparation and
`characterization of cyclamic acid salts of several widely
`used classes of drugs including antihistamines, antibiotics,
`antitussives, myospasmol5rbics, and local anesthetics was
`reported (34,35).
`Various salts of penicillin and basic amine compounds
`have been formulated in an effort to produce a long-acting,
`nonallergenic form of penicillin. Since antihistamines
`appear to mitigate the symptomatology of penicillin re-
`actions in some patients, coadministration of the two has
`been advocated. The preparation of the benzhydralamine
`salt of penicillin was an attempt to produce a repository
`form of penicillin with antiallergic properties (36). Blood
`levels achieved with this salt were comparable to those of
`penicillin G potassium; however, its antiallergic properties
`were not evaluated. In fact, the investigators noted that
`antihistamines can actually cause sensitization at times
`and stated that "despite their occasionally favorable in-
`fluence on the symptoms of penicillin sensitivity, they
`contribute directly to the potential of drug sensitivity when
`co-administered with penicillin."
`Silver salts of sulfanilamide, penicillin, and other anti-
`biotics have been prepared and represent cases where the
`species (ions) are complementary. When aqueous solutions
`of the salts were applied topically to burned tissue, they
`yielded the combined benefits of the oligodlmamic action
`of silver and the advantages of the antibacterial agents
`(37).
`The use of 8-substituted xanthines, particularly the
`8-substituted theophyllines, as salt-forming agents was
`first reported in the preparation of a series of antihistamine
`salts (38-41). Synthesis ofthese xanthine salts was an at-
`tempt to find a drug to counteract the drowsiness caused
`by the antihistamines with the stimulant properties of the
`xanthines. When an electronegative group is introduced
`into the xanthine molecule at the 8-position, the elec-
`tron-drawing capacity of the substituent results in the
`creation of an acidic hydrogen at position Z. Thus, these
`
`4 / Journal of Pharmaceutical Sciences
`
`Sal1
`
`Acetylaminoa
`N-Acetyl-L-a
`N-Acetylcyst
`Adamantoic a
`Adipic acid
`N-Alkylsulfar
`
`Anthraquinor
`Arabogalactar
`Arginine
`
`Aspartate
`Betaine
`Bis(2-carboxy
`Carni{ine
`4-Chloro-m-tr
`Decanoate
`Diacetyl sulfa
`Dibenzylethyl
`Diethylamine
`Diguaiacyl ph
`Dioctyl sulfosr
`Embonic (pan
`
`Fructose 1,6-d
`
`,
`
`can undergo ra11 Table III-
`moderately strong acidic compounds
`formation with various organic bases.
`The 8-halotheophyllines were the first group of xan-
`thines studied as potential salt-forming agents. Since the
`report on the preparation of the 8-chlorotheophylline salt
`of diphenhydramine (42), synthesis of the 8-halotheo-
`phyllinates of a number of organic bases has been at-
`tempted. The 8-chlorotheophylline salts of quinine,
`ephedrine, and strychnine were prepared and character-
`ized (43). These salts were less water soluble than the
`corresponding free alkaloidal bases. In a similar report, the
`8-chlorotheophyllinates of three synthetic narcotics,
`meperidine, levorphanol, and metopon, were prepared
`(44).
`_ Pharmacological and clinical studies involving the g-
`bromotheophylline pyrilamine salt revealed the unusual
`diuretic properties associated with theE-halotheophylline
`portion of the compound (45, 46). This finding initiated
`an investigation into the preparation of a soluble 8-bro-
`motheophylline salt of high diuretic activity. With readily
`available amines, over 30 salts.were synthesized and
`screened for diuretic activity (4?). When tested against
`theophylline salts of the same amines, the 8-bromotheo-
`phyllinates showed greater activity in every case.
`With the successful formation of S-halotheophyllinates
`of organic bases, Morozowich and Bope (48) proposed that,
`if the halogen moiety was replaced with a more electro-
`negative substituent such as a nitro group, a more acidic
`compound would be formed. Presumably, more stable salts
`would result and precipitation of the free xanthine deriv-
`ative in the stomach would be less likely to occur. On this
`premise, they successfully prepared pharmacologically
`effective 8-nitrotheophyllinates of several pharmaceuti-
`cally useful bases.
`Duesel et al. (Lg), in their study of choline theophylli-
`nate, prepared the 8-chloro-,8-bromo-, and 8-nitrotheo-
`phylline salts of choline. Oral toxicity studies in mice
`showed that the LD56 of the 8-nitrotheophyllinate was
`much greater than that of either 8-halotheophylline. In
`fact, it remained nonlethal at doses as high as 5 g.
`Polygalacturonic acid, a derivative of pectin, has been
`used to prepare quinidine salts exhibiting reduced toxicity
`(49, 50). The compound possesses special demulceni
`properties and inhibits mucosal irritation. The rationale
`for use of this agent is to reduce the ionic shock to the GI
`mucosa resulting from the flood of irritating ions liberated
`by rapid dissociation of the conventional inorganic quin-
`idine salts. Studies have shown that it is foui timeJ less
`toxic orally than the sulfate. This difference was attributed
`to the slower release of quinidine from the polygalactu-
`ronate.
`Other compounds reported to be potentially useful as
`pharmaceutical salt forms are listed in Table III.
`
`Glucose 1-pho
`6-phosphpri
`t,-Glutamine
`Hydroxynaph
`2-(4-lmidazoll
`Isobutanolami
`Lauryl sulfate
`Lvsine
`
`Methanesulfor
`N-Methylgluc
`
`N-Methylpipe
`Morpholine
`2-Naphthalenr
`Octanoate
`Probenecid
`Tannic acid
`Theobromine I
`3,4,5-Trimeth<
`
`Tromethamint
`
`tion, the rel
`ministration
`In a reviel
`"different se
`logically the
`properties."
`panded upor
`nature of th
`salts of the s
`ciably, the ir
`The salt f<
`cochemical tr
`dissolution r
`These prope
`mulation chr
`pharmaceuti
`extensive prr
`properties ol
`suitable form
`concerning s
`tion studies l
`salt form on
`under invest:
`
`PHYSICOCHEMICAL STUDIES
`
`Biological activity of a drug molecule is influenced by
`two factors: its chemical structure and effect at a specific
`site and its ability to reach-and then be rernoved from-
`the site of action. Thus, a knowledge of the physicochem.
`ical properties of a compound that influence its absorption,
`distribution, metabolism, and excretion is essential for a
`complete understanding of the onset and duration of ac-
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 5
`
`

`
`llES oSrapu
`
`-uBx Jo dn(
`aql aculs's'
`?Ps auqldqt
`-oaqlolBr{-8
`-?€ uaoq sE
`'aururnb yc
`-JalcBrBqc I
`aql ueql al
`aql'lJodar J
`'scllocJeu
`pal€dard
`
`a,
`
`-8 aql 3uI^
`I€nsnun aq:
`ou{ldr{dooq
`palerlrur 3u
`-orq-8 aiqn
`dlpuar q1t1
`pu€ pozrsar
`lsurBSB pol
`-oaqlouroJq
`'asei
`saleuqdqd<
`'1uq1 pasodc
`-orlcela aro
`SrprcB alou
`sllBs olqEs (
`-^rJap auql
`sn{} uo'rnc
`.{1ecr3o1oce
`--rlna33ruJBr
`
`-r11dqdoaq1
`-oaqloJlru-[
`ACIUI UI SOI
`sBA\ Aleurlll
`u1 'autt1dqd
`'39r
`uaaq seq'ut
`dlrcrxol pact
`luorFurap
`alBuorl€r
`IC oql ol {c
`po?€raq{ su
`-urnb crueS;
`ssal salurl r
`palnqrr?}? sr
`-n1cep8f,1ot
`
`011
`
`se pyasn d1
`'n
`
`dq pacuang
`crlrcads e 1e
`-ruorJ paA(
`-ruaqcocrsdr
`'uorld.rosqe t
`B JoJ IErluos
`-cE Jo uorlBJ
`
`sluotv IBcltnoc?urrerld Jo srurod lI"S InJosn fIIBIluetod-III aIqW
`luaFy Sururrog-11e9
`palJ1po4 punoduro3
`
`uorl€rrJrpohl
`
`a)uaJaJau
`
`prce crlaceoutueldlacy
`aur8eredse-t-1,t1ecy-,y
`aur1s.{r1,{1aey-1y
`pIcE JroJueluupY
`prcu crdrpy
`seleure;1ns1fr11y-p
`
`prre cruoJlnslp-g'I -ououlnb€rqluv
`(ouIqBrB) e1eJPs uepeleSoqerY
`auturS.ry
`
`al€lrBdsV
`auIel0B
`sauu>1p (,{xo1d- g -uourorqc.{xoqrEr- Z )srfl
`aurlruJBJ
`prce JruoJlnsauenlol- Iu -oJolqc-l
`eJEouBJe0
`a1e3Ps 1.{lacetq
`au r u er paua1,{qla1,izu'aqiI
`auruulf,qlalC
`aleqdsoqd 1.{cetenBtq
`aleuncnsoSlns 1f,1cotq
`(ctourPd) cluoqug
`pr3€
`prce rr.roqdsoqdlp-g' I esolcnrd
`
`asoenl8'p1ce cr.roqdsoqd-1 asornlS
`pIJB ruot{dsoqd-9
`eururElnlc-.I
`aleoqlqdeudxorP.{g
`aururelf q1a(1{1oz€PIIuI-})-Z
`aurIu€iouBlnq0sl
`l.{rn€l
`a1€Jlns
`aursdl
`
`p_rc€ )ruoJlnsaueqlaI^l
`aururecniSl,{q1ey1-1y
`
`au rzeredr d 1dq1a141 -,y
`auqoqd;o1X
`prc€ cruoJlnsaualeqlqdelq-3
`el€ou81r0
`plJauaqord
`prJ€
`f,ruuPJ
`prJB JrlaJE aulluoJqoaqJ
`eluozuaq,{xoqlauruJ-9(t't
`
`aurIu€qlaruoJJ
`
`auqcIcdxog
`urcdruo.rqlr{.rg
`auqodcf,xoq
`sapruenBrql.{1iy
`aurzeradr4
`irqlcrduiy
`uIf,l{ruoJuIT
`urxaleqda3
`sprole{I€ snolre^
`sut.todsoPqda3
`urlircruadldzuaqoJlns- D
`urcdutolqilrg
`aur1c,{ce.r1etr,
`saurlldqdoaql(id{lEouIuIY) -t
`urruroJlaIAI
`aueqddxodor4
`1outue1da11
`euIIrrBrt{J
`uqltctdtuY
`surrodsoleqda3
`auqrdce.rle;,
`aurruecurn
`u r.lr{rueuey
`au r loqd.rour;.{qrau- g- 1.{uaq4-3
`aur1c.{cer1a;
`urcdurorqld.rg
`autlcr{ee.r1a.1
`urcduorqldrg
`urc,{urorq$.rg
`urntuaqdag
`utPue13e1so.t4
`euqlf,qdoeql
`eurIueculA
`uqlcruadldzuaqoJlnS-D
`surrodsoPqda3
`(I IVd-Z) aurxoPrlerd
`uqlcruedldzueqoJlns-P
`sur.rodsoPqde3
`auozelnqlduaq4
`surrodsoleqda3
`auaqddxodo.t4
`lourureldag
`uqlctdurerrt4
`saulIu€ snoIJ€A
`auaqddxodor4
`auIlc.{J€r?aJ
`lourui:1hag
`utrtdsY
`(^'ad urpuBlSelsord) ?sordoul(
`
`flllrqnlos
`f lqrqels'dl!^I?re'dlqtqnlog
`eruoruneud ur InJasn lJaJJa paulquroC
`uo1lce PaEuolo't6
`sarlradord ctldaloueEro'.{1rerxo1'dlll}qetS
`(Pro) uotldrosqY
`dlqtqnlog
`uorldrosqe'r(llllq€lS
`uotlce PaEuolo.r4
`.{lrcrxo;
`dltlxol'fycrdocsorS.{q',{llIIqBlS
`dlqtqnlog
`uotldrosqe JrrlsEC
`1ca;ga cr1ce1.{qdo;d pa8uoiord'd1nt1cy
`.{ltcrxo;
`satpado.rd rrldaioueBr6
`uorlce PaEuolo.r4
`flIcIdotsorS^t{'d?111q€1S
`uorlce PaSuolo't4
`uorlca[u1 uo uted PatnPoU
`d?rAtlry
`sailradord crldaloueFr6
`.{lterxoa
`dltctxo;
`d1111qn1og
`fltltqnlog
`dltltqnlog
`dltltqnlog
`.{11irqe1s'd1r,rr1ce'dlqtqnlog
`dlrctxo;
`uorlce PaFuolor4
`drlItq€ts
`satlrado.rd crldaloueS;g
`,{tIf, rdocsor8dq'f111tqe1s'dll)lIoJ
`
`.{lqrqnpg
`,{1rcrdocsor8.{q'd1qiqe1s'.{lrctxo;
`uorlra[u1 fio ured Pe]nPaU
`uoIl)E Jo Jasuo Jals€J
`'f,1tctxo;
`uotlca[u1 uo uted PeJnPaU
`satlrado.ril cr1da1oue3.rI
`uotlle PaSuoio.t4
`satlraclo.td rr1da1ouri8.rI
`uorlce PaBuolor4
`.{1trt1cy
`sarlradord cr1da1oue3.rg
`uorlee PaEuolor4
`(l€ro) uol?drosqV
`alels IBTISfI{d
`
`IS
`Z9
`cc
`v9
`c9
`99
`L9
`8q
`09'6S
`I9
`70
`89
`l9
`99
`o0
`L9
`89
`69
`IL,OL
`ZL
`
`,L
`9L
`9L
`LL
`
`LL
`
`Z9
`8L
`6L
`08
`I8
`Z9
`TO
`78
`Zg
`ZL
`88
`ZL
`t8
`89
`s8
`t8'98
`88
`68
`89
`06
`t-h
`
`-p€ Jo